一项评估两种剂量AP-472作为左旋多巴辅助疗法对伴有运动波动的帕金森病(PD)参与者有效性的研究
一项评估两种剂量AP-472作为左旋多巴辅助疗法对伴有运动波动的帕金森病(PD)参与者有效性的2期、双盲、安慰剂对照研究
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given.
The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Annie Blobaum, Ph.D.
- 电话号码:615-427-1935
- 邮箱:annie@appellopharma.com
学习地点
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205-5551
- 招聘中
- University of Arkansas for Medical Sciences (Site #208)
-
-
California
-
Carlsbad、California、美国、92011
- 招聘中
- Profound Research LLC (Site #222)
-
Los Alamitos、California、美国、90720-3108
- 招聘中
- Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS (Site #217)
-
Los Angeles、California、美国、90033-5310
- 招聘中
- Keck Medicine of USC - USC Healthcare Center 2 (Site #221)
-
Palo Alto、California、美国、94301
- 招聘中
- Parkinson's Research Centers of America (Site #218)
-
-
Colorado
-
Englewood、Colorado、美国、80113-2776
- 招聘中
- Rocky Mountain Clinical Research - CenExel - PPDS (Site #215)
-
-
Florida
-
Boca Raton、Florida、美国、33486
- 招聘中
- Parkinson's Disease & Movement Disorders Center of Boca Raton (Site #227)
-
Boca Raton、Florida、美国、33486
- 招聘中
- UM-UHealth at Boca Raton (Site #226)
-
Hallandale、Florida、美国、33009
- 招聘中
- Velocity Clinical Research - Hallandale Beach (Site #228)
-
Miami、Florida、美国、33136-1051
- 招聘中
- University of Miami (Site #220)
-
Orlando、Florida、美国、32825
- 招聘中
- Neurology One (Site #205)
-
Tampa、Florida、美国、33613-4808
- 招聘中
- USF Parkinson's Disease and Movement Disorders Center (Site #206)
-
-
Georgia
-
Augusta、Georgia、美国、30912-0020
- 招聘中
- Augusta University Medical Center (Site #212)
-
-
Indiana
-
Indianapolis、Indiana、美国、46256
- 招聘中
- Josephson Wallack Munshower Neurology PC (Site #231)
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 招聘中
- The University of Kansas (KU) (Site #216)
-
-
Kentucky
-
Lexington、Kentucky、美国、40536-0001
- 招聘中
- Kentucky Neuroscience Institute (Site #213)
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215-5400
- 招聘中
- Beth Israel Deaconess Medical Center (Site #211)
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan Health System (UMHS) (Site #202)
-
Farmington Hills、Michigan、美国、48334-2973
- 招聘中
- Quest Research Institute - Alcanza - PPDS (Site #201)
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- 招聘中
- University of New Mexico Health Sciences Center (Site #225)
-
-
New York
-
New York、New York、美国、10029-6501
- 招聘中
- Mount Sinai School of Medicine (Site #209)
-
New York、New York、美国、10021
- 招聘中
- Joan and Sanford I. Weill Department of Medicine (Site #224)
-
-
North Carolina
-
Asheville、North Carolina、美国、28806
- 招聘中
- Asheville Neurology Specialists, P.A. (Site #229)
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke Neurological Disorders Clinic (Site #210)
-
-
Ohio
-
Cleveland、Ohio、美国、44195-0001
- 招聘中
- Cleveland Clinic (Site #223)
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University Wexner Medical Center (site #207)
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University Medical Center (Site #204)
-
-
Texas
-
Cypress、Texas、美国、77429
- 招聘中
- Horizon Clinical Research: Gill Neuroscience - Houston (Site #232)
-
Round Rock、Texas、美国、78681-3578
- 招聘中
- Central Texas Neurology Consultants (Site #203)
-
-
Washington
-
Kirkland、Washington、美国、98034-3013
- 招聘中
- EvergreenHealth (Site #219)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
Participants must meet all of the following criteria to take part in the study:
- Be a man or woman between 30 and 80 years of age at the time of screening.
- Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movement and symptoms that affect one side of the body more than the other.
- Have mild to moderate Parkinson's disease, defined as stage 3 or lower on the Hoehn and Yahr scale when medications are working ("ON" state).
- Experience an average of at least 3 hours of OFF time per day, based on home symptom diaries, with at least 2.5 hours of OFF time each day during the baseline period.
- Have a Montreal Cognitive Assessment (MoCA) score of 24 or higher at screening.
- Be able to walk independently, with or without the use of a walking aid.
- Be able to swallow oral medication.
- Have been on a stable Parkinson's medication regimen for at least 4 weeks before screening. Medications known as MAO-B inhibitors must have been stable for at least 12 weeks.
- Be taking levodopa at least four times daily (immediate- or controlled-release formulations) or three times daily (extended-release formulations such as Rytary or Crexont).
Key Exclusion Criteria:
Participants cannot take part in the study if any of the following apply:
- Have a form of parkinsonism that is not typical Parkinson's disease, such as secondary or atypical parkinsonism.
- Have previously received, or plan to receive during the study, advanced Parkinson's therapies such as continuous levodopa or dopamine delivery systems, or Parkinson's disease-related brain surgery.
- Have dyskinesias (involuntary movements) that are severe enough, in the study doctor's opinion, to interfere with participation.
- Have a history of only certain types of dyskinesias (such as OFF-state, diphasic, myoclonic, or dystonic dyskinesias) without typical peak-dose dyskinesias.
- Are currently taking medications that block dopamine, except for low-dose quetiapine (up to 50 mg per day) used for insomnia.
- Routinely use on-demand "rescue" Parkinson's medications more than three times per week.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Oral tablet |
|
实验性的:Low Dose
AP-472 100 mg per day |
Oral tablet Oral tablet |
|
实验性的:High Dose
AP-472 300 mg per day |
Oral tablet |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
AP-472与安慰剂相比,运动日记中平均每日OFF时间较基线的变化(标准化为16小时清醒时间)
大体时间:第 12 周
|
第 12 周
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
相对于基线的无麻烦性运动障碍的ON时间变化(标准化至16小时)
大体时间:第 12 周
|
第 12 周
|
|
|
Change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 2 (Motor Experiences of Daily Living (M-EDL)) score
大体时间:Week 12
|
For MDS-UPDRS Part II (Motor Experiences of Daily Living, M-EDL) there are 13 items each scored from 0 to 4. The total score range is from 0-52. A higher score indicates worse motor impact on daily activities; lower scores are better. |
Week 12
|
|
Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) summary index
大体时间:Week 12
|
For the Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index the score is calculated by averaging the 8 domain scores and converting them to a 0-100 scale. A higher score indicates worse health-related quality of life; lower scores are better. |
Week 12
|
|
Change from baseline in MDS-UPDRS Part III (Motor Examination) score in the best ON state
大体时间:Week 12
|
The MDS-UPDRS Part III includes 33 items, each scored from 0 to 4. The total score range is from 0-132. A higher score indicates worse motor impairment; lower scores are better. |
Week 12
|
|
Change from baseline in Epworth Sleepiness Scale (ESS) total score
大体时间:Week 12
|
The ESS consists of 8 items, each scored from 0 to 3. The total score range is from 0-24. Higher scores indicate greater daytime sleepiness; lower scores are better. |
Week 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.